区域近表面剂量预测乳腺癌放疗湿性脱屑与植入物失败
单中心2017至2022年223例接受常规分割乳腺或胸壁及区域淋巴结放疗的患者中,157例光子与66例质子治疗。腋窝SR3 D2cc是湿性脱屑(AUC=0.657,P=.007)和植入物失败(AUC=0.880,P=.017)的最强剂量学预测因子。腋窝SR3 D2cc≤48 Gy vs >48 Gy的湿性脱屑率为25.8% vs 48.5%(P<.001),植入物失败率为0% vs 20%(P=.006)。
要点
- 腋窝SR3 D2cc是湿性脱屑和植入物失败的最强剂量学预测因子。
- 腋窝SR3 D2cc≤48 Gy组湿性脱屑和植入物失败率均低于>48 Gy组。
- 光子与质子治疗患者的湿性脱屑、非计划重建手术和植入物失败率相似。
核心结论
- 近表面剂量可预测接受光子或质子乳腺或胸壁放疗患者的湿性脱屑和植入物失败。
- 作者认为对皮肤受累低风险的适当患者应考虑限制腋窝SR3 D2cc≤48 Gy。
研究设计与样本
- 单中心纳入2017至2022年接受常规分割乳腺或胸壁及区域淋巴结放疗的患者共223例,其中157例接受光子照射、66例接受质子照射。
- 为所有患者生成近表面层SR3(定义为乳腺或胸壁计划靶区与皮肤内3 mm所界定的体积)用于分析,质治疗中前瞻性使用SR3体积。
- 回顾性将SR3体积细分为腋窝SR3、非腋窝SR3和乳房下SR3区域。
- 采用受试者工作特征曲线下面积(AUC)评价近表面剂量学对皮肤和植入物毒性的区分性能。
- 采用Pearson χ2检验比较光子和质子照射患者美国国家癌症研究所常见不良事件术语标准毒性。
主要发现
- 腋窝SR3 D2cc是湿性脱屑的最强剂量学预测因子(AUC=0.657,P=.007),也是植入物失败的最强剂量学预测因子(AUC=0.880,P=.017)。
- 腋窝SR3 D2cc对腋窝皱褶处湿性脱屑的预测能力更强(AUC=0.728,P<.001)。
- 腋窝SR3 D2cc≤48 Gy组 vs >48 Gy组的湿性脱屑率分别为25.8% vs 48.5%(P<.001)。
- 腋窝SR3 D2cc≤48 Gy组 vs >48 Gy组的植入物失败率分别为0% vs 20%(P=.006)。
- 光子照射组 vs 质子照射组的湿性脱屑率(38.2% vs 27.3%,P=.12)、非计划重建手术率(35.1% vs 18.8%,P=.21)和植入物失败率(8.8% vs 6.3%,P>.99)相似。
关键数值与推荐
- 腋窝SR3 D2cc≤48 Gy vs >48 Gy:湿性脱屑率25.8% vs 48.5%(P<.001),植入物失败率0% vs 20%(P=.006)。
- 腋窝SR3 D2cc预测湿性脱屑的AUC=0.657(P=.007),预测植入物失败的AUC=0.880(P=.017)。
- 腋窝SR3 D2cc预测腋窝皱褶处湿性脱屑的AUC=0.728(P<.001)。
临床怎么用
- 作者认为对皮肤受累低风险的适当患者应考虑限制腋窝SR3 D2cc≤48 Gy。
- SR3体积在质子治疗中前瞻性使用,SR3区域细分(腋窝、非腋窝、乳房下)为回顾性分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We correlated regional near-surface dose with toxic effects and implant complications in patients receiving breast or chest wall irradiation. We also compared toxic effects and implant complications between patients receiving photon or proton irradiation with prospective near-surface dose optimization. METHODS AND MATERIALS: Patients at a single institution who received conventionally fractionated breast or chest wall and regional nodal irradiation from 2017 to 2022 were included. Near-surface rinds (SR3, defined as the volume bound by the breast or chest wall planning target volume and 3 mm in from the skin) were generated for all patients for analysis. SR3 volumes were used prospectively during proton treatment. SR3 volumes were retrospectively subdivided into axillary SR3, nonaxillary SR3, and inframammary SR3 regions. The discrimination performance of near-surface dosimetry for skin and implant toxicity was evaluated using the area under the receiver operating curve (AUC). National Cancer Institute Common Terminology Criteria for Adverse Events toxicity was compared between patients receiving photon versus proton irradiation using the Pearson χ2 test. RESULTS: Of 223 patients, 157 and 66 received photon and proton irradiation, respectively. Axillary SR3 D2cc was the strongest dosimetric predictor of moist desquamation (AUC = 0.657, P = .007) and implant failure (AUC = 0.880, P = .017), driven by a stronger predictive ability for moist desquamation in the axillary fold (AUC = 0.728, P < .001). With axillary SR3 D2cc ≤48 Gy versus >48 Gy, rates of moist desquamation were 25.8% versus 48.5% (P < .001), respectively, and rates of implant failure were 0% versus 20% (P = .006). Rates of moist desquamation (38.2% vs 27.3%, P = .12), unplanned reconstructive surgery (35.1% vs 18.8%, P = .21), and implant failure (8.8% vs 6.3%, P > .99) were similar between patients receiving photon versus proton irradiation. CONCLUSIONS: Near-surface dose predicts moist desquamation and implant failure in patients receiving either photon or proton irradiation of the breast or chest wall. Consideration should be given to limit axillary SR3 D2cc ≤48 Gy in appropriately selected patients considered low-risk of skin involvement of cancer.
引用
- Salari K, Lee JS, Mumaw DA, et al. Regional Near-Surface Dose Predicts Moist Desquamation and Implant Failure in Patients Receiving Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40010652. doi:10.1016/j.ijrobp.2025.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。